nach oben

Die Dermatologie

Erschienen in:

17.08.2021 | Asthma bronchiale | Leitthema

Allergen-Immuntherapie: Facts und FAQs

verfasst von: Dr. V. Mortasawi, W. Pfützner

Erschienen in: Die Dermatologie | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Allergenimmuntherapie (AIT) ist – neben der oft nicht suffizient durchzuführenden Allergenmeidung – die einzige kausale Therapie Ig(Immunglobulin)E-vermittelter Allergien gegen Aeroallergene und Hymenopterengifte. Sie kann je nach Allergen als subkutane Injektion (subkutane Immuntherapie [SCIT]) oder über eine sublinguale Applikation (sublinguale Immuntherapie [SLIT]) erfolgen, kürzlich wurde zudem auch ein Verfahren zur oralen Immuntherapie zur Behandlung der Nahrungsmittelallergie zugelassen. Neben der korrekten Indikationsstellung (positive Anamnese und Diagnostik einer IgE-vermittelten Allergie, Allergenkarenz nicht ausreichend möglich) sind mögliche Kontraindikationen und Risikofaktoren zu beachten. Zudem kann es unter einer AIT zu – potenziell auch lebensgefährlichen – Nebenwirkungen kommen. Im Folgenden sollen häufig gestellte Fragen und Fakten zur Entscheidungsfindung für die Durchführung und zum Risikomanagement der AIT beleuchtet und unter Berücksichtigung der aktuellen Datenlage diskutiert werden.

Adelmeyer J, Pickert J, Pfützner W, Möbs C (2021) Langfristige Auswirkungen der Allergen-Immuntherapie mit Hymenopterengift auf den klinischen Verlauf, immunologische Parameter und psychosoziale Aspekte. AL 44(02):139–150. https://doi.org/10.5414/ALX02175CrossRef

Alvarez-Cuesta E, Beristain A (2003) Practical management of immunotherapy. Rev Fr Allergol Immunol Clin 43(5):301–309. https://doi.org/10.1016/S0335-7457(03)00194-1CrossRef

Alvarez-Twose I, González-de-Olano D, Sánchez-Muñoz L, Matito A, Jara-Acevedo M, Teodosio C, García-Montero A, Morgado JM, Orfao A, Escribano L (2012) Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol 157(3):275–280. https://doi.org/10.1159/000329856CrossRefPubMed

Ameratunga R, Gillis D, Gold M, Linneberg A, Elwood JM (2017) Evidence refuting the existence of autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA). J Allergy Clin Immunol Pract 5(6):1551–1555.e1. https://doi.org/10.1016/j.jaip.2017.06.033CrossRefPubMed

Amin HS, Liss GM, Bernstein DI (2006) Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 117(1):169–175. https://doi.org/10.1016/j.jaci.2005.10.010CrossRefPubMed

Bilò MB, Tontini C, Martini M, Corsi A, Agolini S, Antonicelli L (2019) Clinical aspects of hymenoptera venom allergy and venom immunotherapy. Eur Ann Allergy Clin Immunol 51(6):244–258. https://doi.org/10.23822/EurAnnACI.1764-1489.113CrossRefPubMed

Bonadonna P, Zanotti R, Caruso B, Castellani L, Perbellini O, Colarossi S, Chilosi M, Dama A, Schiappoli M, Pizzolo G, Senna G, Passalacqua G (2008) Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and hymenoptera allergy. J Allergy Clin Immunol 121(1):256–257. https://doi.org/10.1016/j.jaci.2007.10.014CrossRefPubMed

Bonadonna P, Zanotti R, Müller U (2010) Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 10(4):347–353. https://doi.org/10.1097/ACI.0b013e32833b280cCrossRefPubMed

Bonadonna P, Gonzalez-de-Olano D, Zanotti R, Riccio A, De Ferrari L, Lombardo C, Rogkakou A, Escribano L, Alvarez-Twose I, Matito A, Vega A, Passalacqua G (2013) Venom immunotherapy in patients with clonal mast cell disorders. Efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 1(5):474–478. https://doi.org/10.1016/j.jaip.2013.06.014CrossRefPubMed

10.

Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, Franchini M, Reccardini F, Costantino MT, Roncallo C, Mauro M, Boni E, Rizzini FL, Bilò MB, Marcarelli AR, Passalacqua G (2018) Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy. A clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract 6(4):1368–1372. https://doi.org/10.1016/j.jaip.2017.11.025CrossRefPubMed

11.

Bonadonna P, Mauro M, Preziosi D, Pravettoni V (2020) Pregnancy and hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 20(5):465–469. https://doi.org/10.1111/all.14352CrossRefPubMed

12.

Bousquet J, Mantzouranis E, Cruz AA et al (2010) Uniform definition of asthma severity, control, and exacerbations. Document presented for the World Health Organization consultation on severe asthma. J Allergy Clin Immunol 126(5):926–938. https://doi.org/10.1016/j.jaci.2010.07.019CrossRefPubMed

13.

Brockow K, Kiehn M, Riethmüller C, Vieluf D, Berger J, Ring J (1997) Efficacy of antihistamine pretreatment in the prevention of adverse reactions to hymenoptera immunotherapy. A prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 100(4):458–463. https://doi.org/10.1016/s0091-6749(97)70135-0CrossRefPubMed

14.

Brown SGA (2004) Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114(2):371–376. https://doi.org/10.1016/j.jaci.2004.04.029CrossRefPubMed

15.

Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17(4):233–247. https://doi.org/10.1038/nri.2017.1CrossRefPubMed

16.

Calabria CW, Hauswirth DW, Rank M, Sher L, Larenas-Linnemann D (2017) American academy of asthma, allergy & immunology membership experience with venom immunotherapy in chronic medical conditions and pregnancy, and in young children. Allergy Asthma Proc 38(2):121–129. https://doi.org/10.2500/aap.2017.38.4024CrossRefPubMed

17.

Calderón MA, Simons FER, Malling H‑J, Lockey RF, Moingeon P, Demoly P (2012) Sublingual allergen immunotherapy. Mode of action and its relationship with the safety profile. Allergy 67(3):302–311. https://doi.org/10.1111/j.1398-9995.2011.02761.xCrossRefPubMed

18.

Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG (2017) Prevention and management of glucocorticoid-induced side effects. A comprehensive review: infectious complications and vaccination recommendations. J Am Acad Dermatol 76(2):191–198. https://doi.org/10.1016/j.jaad.2016.02.1240CrossRefPubMed

19.

Cari L, De Rosa F, Nocentini G, Riccardi C (2019) Context-dependent effect of glucocorticoids on the proliferation, differentiation, and apoptosis of regulatory T cells. A review of the empirical evidence and clinical applications. Int J Mol Sci. https://doi.org/10.3390/ijms20051142CrossRefPubMedPubMedCentral

20.

Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D (2011) Allergen immunotherapy. A practice parameter third update. J Allergy Clin Immunol 127(1):S1–55. https://doi.org/10.1016/j.jaci.2010.09.034CrossRefPubMed

21.

Franco LM, Gadkari M, Howe KN, Sun J, Kardava L, Kumar P, Kumari S, Hu Z, Fraser IDC, Moir S, Tsang JS, Germain RN (2019) Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J Exp Med 216(2):384–406. https://doi.org/10.1084/jem.20180595CrossRefPubMedPubMedCentral

22.

Golden DBK (2010) Long-term outcome after venom immunotherapy. Curr Opin Allergy Clin Immunol 10(4):337–341. https://doi.org/10.1097/ACI.0b013e32833bc0baCrossRefPubMed

23.

González de Olano D, Alvarez-Twose I, Esteban-López MI, Sánchez-Muñoz L, de Durana MDAD, Vega A, García-Montero A, González-Mancebo E, Belver T, Herrero-Gil MD, Fernández-Rivas M, Orfao A, de la Hoz B, Castells MC, Escribano L (2008) Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with hymenoptera venom anaphylaxis. J Allergy Clin Immunol 121(2):519–526. https://doi.org/10.1016/j.jaci.2007.11.010CrossRefPubMed

24.

Hiatt WR, Wolfel EE, Stoll S, Nies AS, Zerbe GO, Brammell HL, Horwitz LD (1985) Beta‑2 adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. Clin Pharmacol Ther 37(1):2–6. https://doi.org/10.1038/clpt.1985.2CrossRefPubMed

25.

Jarkvist J, Salehi C, Akin C, Gülen T (2020) Venom immunotherapy in patients with clonal mast cell disorders. IgG4 correlates with protection. Allergy 75(1):169–177. https://doi.org/10.1111/all.13980CrossRefPubMed

26.

Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, Cox L, Demoly P, Frew AJ, O’Hehir R, Kleine-Tebbe J, Muraro A, Lack G, Larenas D, Levin M, Nelson H, Pawankar R, Pfaar O, van Ree R, Sampson H, Santos AF, Du Toit G, Werfel T, van Gerth Wijk R, Zhang L, Akdis CA (2015) International consensus on allergy immunotherapy. J Allergy Clin Immunol 136(3):556–568. https://doi.org/10.1016/j.jaci.2015.04.047CrossRefPubMed

27.

Kerzerho J, Wunsch D, Szely N, Meyer H‑A, Lurz L, Röse L, Wahn U, Akbari O, Stock P (2012) Effects of systemic versus local administration of corticosteroids on mucosal tolerance. J Immunol 188(1):470–476. https://doi.org/10.4049/jimmunol.1101405CrossRefPubMed

28.

Klimek L, Jutel M, Akdis C et al (2020) Handling of allergen immunotherapy in the COVID-19 pandemic. An ARIA-EAACI statement. Allergy 75(7):1546–1554. https://doi.org/10.1111/all.14336CrossRefPubMed

29.

Klimek L, Bergmann K‑C, Brehler R, Pfützner W, Worm M, Hartmann K, Jakob T, Novak N, Ring J, Hamelmann E, Ankermann T, Schmidt SM, Untersmayr E, Hötzenecker W, Jensen-Jarolim E, Zuberbier T (2021) Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe. Allergo J 30(3):22–43. https://doi.org/10.1007/s15007-021-4773-1CrossRefPubMedPubMedCentral

30.

Klimek L (2017) Allergenspezifische Immuntherapie: Gute Praxis und innovative Ansätze. Dtsch Arztebl 114(12):A-587–C-493

31.

Lang DM (1995) Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Saf 12(5):299–304. https://doi.org/10.2165/00002018-199512050-00002CrossRefPubMed

32.

Larenas-Linnemann DES, Hauswirth DW, Calabria CW, Sher LD, Rank MA (2016) American academy of allergy, asthma & immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. Allergy Asthma Proc 37(5):112–122. https://doi.org/10.2500/aap.2016.37.3981CrossRefPubMed

33.

Ledford DK (2021) Allergen immunotherapy in patient receiving methotrexate. https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2021/allergen-immuno. Zugegriffen: 04.06.2021

34.

Lee S, Hess EP, Nestler DM, Bellamkonda Athmaram VR, Bellolio MF, Decker WW, Li JTC, Hagan JB, Manivannan V, Vukov SC, Campbell RL (2013) Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol 131(4):1103–1108. https://doi.org/10.1016/j.jaci.2013.01.011CrossRefPubMed

35.

Linneberg A, Jacobsen RK, Jespersen L, Abildstrøm SZ (2012) Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 129(2):413–419. https://doi.org/10.1016/j.jaci.2011.09.007CrossRefPubMed

36.

Malipiero G, Melone G, Puggioni F, Pawankar R, Heffler E, Paoletti G (2021) Allergen immunotherapy and biologics in respiratory allergy. Friends or foes? Curr Opin Allergy Clin Immunol 21(1):16–23. https://doi.org/10.1080/02770903.2019.1658204CrossRefPubMed

37.

Metzger WJ, Turner E, Patterson R (1978) The safety of immunotherapy during pregnancy. J Allergy Clin Immunol 61(4):268–272. https://doi.org/10.1016/0091-6749(78)90202-6CrossRefPubMed

38.

Möbs C, Ipsen H, Mayer L, Slotosch C, Petersen A, Würtzen PA, Hertl M, Pfützner W (2012) Birch pollen immunotherapy results in long-term loss of Bet v 1‑specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. J Allergy Clin Immunol 130(5):1108–1116.e6. https://doi.org/10.1016/j.jaci.2012.07.056CrossRefPubMed

39.

Mock BA, Peiker G, Markert UR, Jäger L (2000) Spezifische Immuntherapie (Hyposensibilisierung) mit Insektengift in der Schwangerschaft. Z Geburtshilfe Neonatol 204(3):117–119. https://doi.org/10.1055/s-2000-10207CrossRefPubMed

40.

Morel J, Czitrom SG, Mallick A, Sellam J, Sibilia J (2016) Vaccinations in adults with chronic inflammatory joint disease. Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs. Joint Bone Spine 83(2):135–141. https://doi.org/10.1016/j.jbspin.2015.08.008CrossRefPubMed

41.

Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB (2004) Development of the asthma control test. A survey for assessing asthma control. J Allergy Clin Immunol 113(1):59–65. https://doi.org/10.1016/j.jaci.2003.09.008CrossRefPubMed

42.

Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, Friedrichs F, Fuchs T, Hamelmann E, Hartwig-Bade D, Hering T, Huttegger I, Jung K, Klimek L, Kopp MV, Merk H, Rabe U, Saloga J, Schmid-Grendelmeier P, Schuster A, Schwerk N, Sitter H, Umpfenbach U, Wedi B, Wöhrl S, Worm M, Kleine-Tebbe J, Kaul S, Schwalfenberg A (2014) Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. S2k guideline of the German society for allergology and clinical immunology (DGAKI), the society for pediatric allergy and environmental medicine (GPA), the medical association of German allergologists (AeDA), the Austrian society for allergy and immunology (ÖGAI), the Swiss society for allergy and immunology (SGAI), the German society of dermatology (DDG), the German society of oto-rhino-laryngology, head and neck surgery (DGHNO-KHC), the German society of pediatrics and adolescent medicine (DGKJ), the society for pediatric pneumology (GPP), the German respiratory society (DGP), the German association of ENT surgeons (BV-HNO), the professional federation of paediatricians and youth doctors (BVKJ), the federal association of pulmonologists (BDP) and the German dermatologists association (BVDD). Allergo J Int 23(8):282–319. https://doi.org/10.1007/s40629-014-0032-2CrossRefPubMedPubMedCentral

43.

Pfützner W, Schuppe M (2021) Use of biologics in allergen immunotherapy. Allergol Select 5:108–118. https://doi.org/10.5414/ALX02206ECrossRefPubMedPubMedCentral

44.

Picolo G, Hisada M, Moura AB, Machado MFM, Sciani JM, Conceição IM, Melo RL, Oliveira V, Lima-Landman MTR, Cury Y, Konno K, Hayashi MAF (2010) Bradykinin-related peptides in the venom of the solitary wasp cyphononyx fulvognathus. Biochem Pharmacol 79(3):478–486. https://doi.org/10.1016/j.bcp.2009.08.020CrossRefPubMed

45.

Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ, Rodriguez del Rio P, Tsoumani M, Gawlik R, Paraskevopoulos G, Ruëff F, Valovirta E, Papadopoulos NG, Calderón MA (2015) Clinical contraindications to allergen immunotherapy. An EAACI position paper. Allergy 70(8):897–909. https://doi.org/10.1111/all.12638CrossRefPubMed

46.

Pitsios C, Tsoumani M, Bilò MB, Sturm GJ, Rodríguez Del Río P, Gawlik R, Ruëff F, Paraskevopoulos G, Valovirta E, Pfaar O, Calderón MA, Demoly P (2019) Contraindications to immunotherapy. A global approach. Clin Transl Allergy 9:45. https://doi.org/10.1186/s13601-019-0285-4CrossRefPubMedPubMedCentral

47.

Przybilla B (2011) Diagnose und Therapie der Bienen- und Wespengiftallergie (Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), der Deutschen Dermatologischen Gesellschaft (DDG) und der Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ) in Zusammenarbeit mit der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und der Schweizerischen Gesellschaft für Allergologie und Immunologie (SGAI))CrossRef

48.

Przybilla B, Ruëff F, Walker A, Räwer H‑C, Aberer W, Bauer CP, Berdel D, Biedermann T, Brockow K, Forster J, Fuchs T, Hamelmann E, Jakob T, Jarisch R, Merk HF, Müller U, Ott H, Sitter W, Urbanek R, Wedi B (2011) Diagnose und Therapie der Bienen- und Wespengiftallergie. Allergo J 20(6):318–339. https://doi.org/10.1007/BF03362543CrossRef

49.

Roberts G, Pfaar O, Akdis CA et al (2018) EAACI guidelines on allergen immunotherapy. Allergic rhinoconjunctivitis. Allergy 73(4):765–798. https://doi.org/10.1111/all.13317CrossRefPubMed

50.

Ruëff F, Wenderoth A, Przybilla B (2001) Patients still reacting to a sting challenge while receiving conventional hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108(6):1027–1032. https://doi.org/10.1067/mai.2001.119154CrossRefPubMed

51.

Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Körner M, Kucharewicz I, Küchenhoff H, Lang R, Quercia O, Reider N, Severino M, Sticherling M, Sturm GJ, Wüthrich B (2009) Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy. Importance of baseline serum tryptase—a study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. J Allergy Clin Immunol 124(5):1047–1054. https://doi.org/10.1016/j.jaci.2009.08.027CrossRefPubMed

52.

Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Kucharewicz I, Küchenhoff H, Lang R, Quercia O, Reider N, Severino M, Sticherling M, Sturm GJ, Wüthrich B (2010) Predictors of side effects during the buildup phase of venom immunotherapy for hymenoptera venom allergy. The importance of baseline serum tryptase. J Allergy Clin Immunol 126(1):105–111.e5. https://doi.org/10.1016/j.jaci.2010.04.025CrossRefPubMed

53.

Ruëff F, Vos B, Oude Elberink J, Bender A, Chatelain R, Dugas-Breit S, Horny H‑P, Küchenhoff H, Linhardt A, Mastnik S, Sotlar K, Stretz E, Vollrath R, Przybilla B, Flaig M (2014) Predictors of clinical effectiveness of hymenoptera venom immunotherapy. Clin Exp Allergy 44(5):736–746. https://doi.org/10.1111/cea.12275CrossRefPubMed

54.

Schwartz HJ, Golden DB, Lockey RF (1990) Venom immunotherapy in the hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 85(4):709–712. https://doi.org/10.1016/0091-6749(90)90188-aCrossRefPubMed

55.

Shaikh WA, Shaikh SW (2012) A prospective study on the safety of sublingual immunotherapy in pregnancy. Allergy 67(6):741–743. https://doi.org/10.1111/j.1398-9995.2012.02815.xCrossRefPubMed

56.

Simons FER, Schatz M (2012) Anaphylaxis during pregnancy. J Allergy Clin Immunol 130(3):597–606. https://doi.org/10.1016/j.jaci.2012.06.035CrossRefPubMed

57.

Smith DM, Coop CA, Freeman TM (2020) β‑Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy. Are risks related to individual product safety profile? Curr Opin Allergy Clin Immunol 20(4):401–406. https://doi.org/10.1097/ACI.0000000000000657CrossRefPubMed

58.

Steiner UC, Furrer H, Helbling A (2009) Specific immunotherapy in a pollen-allergic patient with human immunodeficiency virus infection. World Allergy Organ J 2(4):57–58. https://doi.org/10.1097/WOX.0b013e31819bcae7CrossRefPubMedPubMedCentral

59.

Stoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A (2014) Angiotensin-converting enzyme inhibitors do not impair the safety of hymenoptera venom immunotherapy build-up phase. Clin Exp Allergy 44(5):747–755. https://doi.org/10.1111/cea.12276CrossRefPubMed

60.

Stoevesandt J, Hosp C, Kerstan A, Trautmann A (2015) Hymenoptera venom immunotherapy while maintaining cardiovascular medication. Safe and effective. Ann Allergy Asthma Immunol 114(5):411–416. https://doi.org/10.1016/j.anai.2015.03.001CrossRefPubMed

61.

Sturm GJ, Varga E‑M, Roberts G et al (2018) EAACI guidelines on allergen immunotherapy. Hymenoptera venom allergy. Allergy 73(4):744–764. https://doi.org/10.1111/all.13262CrossRefPubMed

62.

Sturm GJ, Herzog SA, Aberer W et al (2021) β‑blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy. Allergy 76(7):2166–2176. https://doi.org/10.1111/all.14785CrossRefPubMed

63.

Toussirot É, Bereau M (2015) Vaccination and induction of autoimmune diseases. Inflamm Allergy Drug Targets 14(2):94–98. https://doi.org/10.2174/1871528114666160105113046CrossRefPubMed

64.

Ugor E, Prenek L, Pap R, Berta G, Ernszt D, Najbauer J, Németh P, Boldizsár F, Berki T (2018) Glucocorticoid hormone treatment enhances the cytokine production of regulatory T cells by upregulation of Foxp3 expression. Immunobiology 223(4-5):422–431. https://doi.org/10.1016/j.imbio.2017.10.010CrossRefPubMed

65.

van Anrooij B, van der Veer E, de Monchy JGR, van der Heide S, Kluin-Nelemans JC, van Voorst Vader PC, van Doormaal JJ, Oude Elberink JNG (2013) Higher mast cell load decreases the risk of hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol 132(1):125–130. https://doi.org/10.1016/j.jaci.2012.12.1578CrossRefPubMed

66.

Virchow JC (2019) Allergen immunotherapy (AIT) in asthma. Semin Immunol 46:101334. https://doi.org/10.1016/j.smim.2019.101334CrossRefPubMed

67.

Walker SM, Durham SR, Till SJ, Roberts G, Corrigan CJ, Leech SC, Krishna MT, Rajakulasingham RK, Williams A, Chantrell J, Dixon L, Frew AJ, Nasser SM (2011) Immunotherapy for allergic rhinitis. Clin Exp Allergy 41(9):1177–1200. https://doi.org/10.1111/j.1365-2222.2011.03794.xCrossRefPubMed

68.

Wedi B, Ruëff F (2011) Pharmakoprophylaxe und Begleitmedikation bei spezifischer Immuntherapie. Hautarzt 62(9):663–670. https://doi.org/10.1007/s00105-011-2157-2CrossRefPubMed

69.

White JL, Greger KC, Lee S, Kahoud RJ, Li JT, Lohse CM, Campbell RL (2018) Patients taking β‑blockers do not require increased doses of epinephrine for anaphylaxis. J Allergy Clin Immunol Pract 6(5):1553–1558.e1. https://doi.org/10.1016/j.jaip.2017.12.020CrossRefPubMed

70.

Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, Perbellini O, Rossini M, Schena D, Busa M, Marcotulli MC, Bilò MB, Franchini M, Marchi G, Simioni L, Bonadonna P (2015) Clonal mast cell disorders in patients with severe hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 136(1):135–139. https://doi.org/10.1016/j.jaci.2014.11.035CrossRefPubMed

Titel: Allergen-Immuntherapie: Facts und FAQs
verfasst von: Dr. V. Mortasawi
W. Pfützner
Publikationsdatum: 17.08.2021
Verlag: Springer Medizin
Schlagwörter: Asthma bronchiale
Allergologie in der HNO-Heilkunde
Anaphylaxie
Mastozytose
Anaphylaxie
Allergenspezifische Immuntherapie
Allergenspezifische Immuntherapie
Erschienen in: Die Dermatologie / Ausgabe 9/2021
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI: https://doi.org/10.1007/s00105-021-04872-8

Passend zum Thema

Anaphylaxie

Es wäre so einfach, ein Leben zu retten – Wenn man nur daran denkt…

Anaphylaxie ist eine akute schwere allergische Reaktion und somit die schwerste Komplikation in der Allergologie. Darauf sollten Ärztinnen und Ärzte vorbereitet sein.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2021

Eine seltene Ursache von lividen retikulären Hautzeichnungen

Quincke-Ödem oder kutanes Angiosarkom?

Egon Erwin Kischs syphilitischer Mädchenhirt Jarda und der Prager Dermatologieprofessor Karl Kreibich

Bedeutung der molekularen Diagnostik für die Allergenimmuntherapie

Der Dermatovenerologe Gottfried Benn

Erratum zu: Klinische, pathologische und molekulare Biomarker der Hidradenitis suppurativa/Acne inversa

Passend zum Thema

Es wäre so einfach, ein Leben zu retten – Wenn man nur daran denkt…